Sol-Gel Technologies Ltd. (SLGL)Healthcare | Biotechnology | Ness Ziona, Israel | NasdaqCM
68.81 USD
-3.76
(-5.181%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 68.81 |
Hot Take ↕ | Aug. 22, 2026, 3:31 a.m. EDT
The investment case here is fundamentally broken despite the recent price rally. While the stock has surged 226% year-over-year, this recovery is masking a catastrophic seven-year decline where the business lost over 65% of its value. The core business is deteriorating rapidly, with revenue collapsing by 96.6% and operating margins deeply negative. The company is burning cash aggressively, with free cash flow and operating cash flow both in the millions of dollars in the red, while holding minimal debt relative to its tiny market cap. There is no dividend to provide any income cushion. The recent price spike appears to be driven entirely by speculative capital inflows from activist investors rather than operational improvement, as the company continues to report losses and lag revenue estimates. The statistical forecast suggests a slight upward lean over the next month, but given the lack of fundamental support and the precarious nature of the business, this momentum is fragile and likely to reverse once the speculative buying dries up. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.044191 |
| AutoARIMA | 0.052513 |
| AutoETS | 0.085270 |
| MSTL | 0.094936 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 19.29 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.110 |
| Excess Kurtosis | 0.82 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.601 |
| Revenue per Share | 0.615 |
| Market Cap | 225,283,856 |
| Forward P/E | -8.93 |
| Beta | 1.16 |
| Website | https://www.sol-gel.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 2.0620253 |
| Address1 | 7 Golda Meir Street |
| Address2 | Weizmann Science Park |
| All Time High | 210.0 |
| All Time Low | 3.34 |
| Ask | 81.0 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 56,330 |
| Average Daily Volume3 Month | 45,029 |
| Average Volume | 45,029 |
| Average Volume10Days | 56,330 |
| Beta | 1.158 |
| Bid | 70.39 |
| Bid Size | 10 |
| Book Value | 14.69 |
| City | Ness Ziona |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 68.81 |
| Current Ratio | 10.368 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 76.0 |
| Day Low | 66.15 |
| Debt To Equity | 1.601 |
| Display Name | Sol-Gel |
| Earnings Timestamp | 1,787,229,000 |
| Earnings Timestamp End | 1,795,091,400 |
| Earnings Timestamp Start | 1,795,091,400 |
| Ebitda | -17,690,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.069 |
| Enterprise To Revenue | 99.234 |
| Enterprise Value | 178,124,864 |
| Eps Current Year | -9.475 |
| Eps Forward | -7.7025 |
| Eps Trailing Twelve Months | -5.62 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 78.79 |
| Fifty Day Average Change | -9.980003 |
| Fifty Day Average Change Percent | -0.12666586 |
| Fifty Two Week Change Percent | 206.20253 |
| Fifty Two Week High | 97.97 |
| Fifty Two Week High Change | -29.160004 |
| Fifty Two Week High Change Percent | -0.29764217 |
| Fifty Two Week Low | 22.043 |
| Fifty Two Week Low Change | 46.767 |
| Fifty Two Week Low Change Percent | 2.121626 |
| Fifty Two Week Range | 22.043 - 97.97 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,517,495,400,000 |
| Float Shares | 534,120 |
| Forward Eps | -7.7025 |
| Forward P E | -8.933463 |
| Free Cashflow | -2,120,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 28 |
| Fullday Change | -3.76 |
| Fullday Change Percent | -5.18121 |
| Fullday Price | 68.81 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -14,025,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.59611 |
| Held Percent Institutions | 0.41469002 |
| Implied Shares Outstanding | 3,273,999 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,746,403,200 |
| Last Split Factor | 1:10 |
| Long Business Summary | Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. |
| Long Name | Sol-Gel Technologies Ltd. |
| Market | us_market |
| Market Cap | 225,283,856 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_621569 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -16,337,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 237,594,107 |
| Number Of Analyst Opinions | 3 |
| Open | 74.485 |
| Operating Cashflow | -8,542,000 |
| Operating Margins | -7.0422997 |
| Payout Ratio | 0.0 |
| Phone | 972 8 931 3433 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 68.81 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 72.57 |
| Price Eps Current Year | -7.2622685 |
| Price Hint | 2 |
| Price To Book | 4.684139 |
| Price To Sales Trailing12 Months | 125.506325 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.873 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -3.76 |
| Regular Market Change Percent | -5.18121 |
| Regular Market Day High | 76.0 |
| Regular Market Day Low | 66.15 |
| Regular Market Day Range | 66.15 - 76.0 |
| Regular Market Open | 74.485 |
| Regular Market Previous Close | 72.57 |
| Regular Market Price | 68.81 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 147,789 |
| Return On Assets | -0.23868 |
| Return On Equity | -0.40854 |
| Revenue Growth | -0.966 |
| Revenue Per Share | 0.615 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,273,999 |
| Shares Percent Shares Out | 0.0150999995 |
| Shares Short | 49,599 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 46,652 |
| Short Name | Sol-Gel Technologies Ltd. |
| Short Percent Of Float | 0.0469 |
| Short Ratio | 0.87 |
| Source Interval | 15 |
| Symbol | SLGL |
| Target High Price | 285.0 |
| Target Low Price | 110.0 |
| Target Mean Price | 196.66667 |
| Target Median Price | 195.0 |
| Total Cash | 47,929,000 |
| Total Cash Per Share | 14.639 |
| Total Debt | 770,000 |
| Total Revenue | 1,795,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.62 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 68.30858 |
| Two Hundred Day Average Change | 0.50141907 |
| Two Hundred Day Average Change Percent | 0.007340499 |
| Type Disp | Equity |
| Volume | 147,789 |
| Website | https://www.sol-gel.com |
| Zip | 7,403,650 |